Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: A potential new treatment for infectious keratitis

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 8, 2008, Pages 3402-3408

  Martins, Suy Anne R ^a   Combs, Juan Castro ^a   Noguera, Guillermo ^a   Camacho, Walter ^a   Wittmann, Priscila ^a   Walther, Rhonda ^b   Cano, Marisol ^a   Dick, James ^b   Behrens, Ashley ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOFLAVIN; FLAVINE MONONUCLEOTIDE; PHOTOSENSITIZING AGENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CALCULATION; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGUS; FUNGUS GROWTH; FUNGUS ISOLATION; GROWTH INHIBITION; IN VITRO STUDY; KERATITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; ULTRAVIOLET A RADIATION; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; BACTERIUM; COMPARATIVE STUDY; CORNEA ULCER; DRUG EFFECT; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; RADIATION EXPOSURE; ULTRAVIOLET RADIATION;

BACTERIA; CANDIDA ALBICANS; COLONY COUNT, MICROBIAL; COMBINED MODALITY THERAPY; CORNEAL ULCER; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FLAVIN MONONUCLEOTIDE; FUNGI; PHOTOSENSITIZING AGENTS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; ULTRAVIOLET RAYS; ULTRAVIOLET THERAPY;

EID: 49049114100     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1592     Document Type: Article

References (59)

1. Bennett HGB, Hay J, Devonshire P, Kirkness CM, Seal DV. Antimicrobial management of presumed microbial keratitis: guidelines for treatment of central and peripheral ulcers. Br J Ophthalmol. 1998;82:137-145.
2. Seal DV, Bron AJ, Hay J. Ocular Infection: Investigation and Treatment in Practice. London: Martin Dunitz; 1998.
3. Jones DB. Decision-making in the management of microbial keratitis. Ophthalmology. 1981;88:814-820.
4. Neu HC. The crisis in antibiotic resistance. Science. 1992;257:1064-1073.
5. DeMuri GP, Hostetter MK. Resistance to antifungal agents. Pediatr Clin North Am. 1995;42:665-685.
6. Dever LL, Handwerger S. Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. Microb Drug Resist. 1996;2:415-421.
7. Glynn MK, Bopp C, Dewitt W, et al. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med. 1998;338:1333-1338.
8. Levy SB. Multidrug resistance: a sign of the times. N Engl J Med. 1998;338:1376-1378.
9. Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother. 1990;26:165-179.
10. Chin GJ, Marx Je. Resistance to antibiotics. Science 1994;264:359-393.
11. Fass RJ, Barnishan J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother. 1995;36:343-353.
12. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999;106:1319-1323.
13. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313-1318.
14. Humphreys H, Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus (letter). Lancet. 1985;2:383.
15. Knauf HP, Silvany R, Southern PMJ, et al. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea. 1996;15:66-71.
16. Maffett M, O'Day DM. Ciprofloxacin-resistant bacterial keratitis (letter). Am J Ophthalmol. 1993;115:545-546.
17. Smith SM, Eng RHK, Bais P, et al. Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1990;26:567-572.
18. Snyder ME, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1992;114:336-338.
19. Thomson KS, Sanders CC, Hayden ME. In vitro studies with 5 quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother. 1991;35:2329-2334.
20. Daum TE, Schaberg DR, Terpenning MS, et al. Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother. 1990;34:1862-1863.
21. Cohen MA, Huband MD. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis. 1999;33:43-46.
22. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med. 1996;156:2579-2584.
23. Tsugita A, Okada Y, Uchara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965;103:360-363.
24. Goodrich RP. The use of riboflavin for inactivation of pathogens in blood products. Vox Sang. 2000;78(suppl 2):211-215.
25. Samar BM, Goodrich RP. Viral inactivation in plasma using riboflavin-based technology. Transfusion. 2001;41(suppl):88S.
26. McAteer MJ, Tay-Goodrich B, Doane S, et al. Photoinactivation of virus in packed red blood cell units using riboflavin and visible light. Transfusion. 2000;40(suppl):99S.
27. Shechmeister IL. Sterilization by ultraviolet irradiation. In: Block SS, ed. Disinfection, sterilization and preservation, 4th ed. Philadelphia: Lea & Febiger; 1991:553-565.
28. Russell AD. Radiation sterilization. In: Russell AD, Hugo WB, Ayliffe GAJ, eds. Principles and Practice of Disinfection, Preservation and Sterilization. 3rd ed. Oxford, UK: Blackwell Science; 1999:675-702.
29. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135:620-627.
30. Wollensak G, Sporl E, Seiler T. Treatment of keratoconus by collagen crosslinking (in German). Ophthalmologe. 2003;100:44-49.
31. Kaufman HE. Strengthening the cornea. Cornea. 2004;23:432.
32. Labetoulle M. An alternative to corneal transplantation in keratoconus treatment? J Fr Ophtalmol. 2003;26:1097-1098.
33. Seiler T, Huhle S, Spoerl E, Kunath H. Manifest diabetes and keratoconus: a retrospective case: control study. Graefe's Arch Clin Exp Ophthalmol. 2000;238:822-825.
34. Sady C, Khosrof S, Nagaraj R. Advanced Maillard reaction and crosslinking of corneal collagen in diabetes. Biochem Biophys Res Commun. 1995;214:793-797.
35. Andreassen TT, Simonsen AH, Oxlund H. Biomechanical properties of keratoconus and normal corneas. Exp Eye Res. 1980;31:435-441.
36. Kohlhaas M, Sandner D, Spoerl E, Pillunat LE. Behandlung der Keratektasie nach Lasik durch Kollagen-crosslinking. In: Pham DT, Auffarth GU, Wirbelauer Ch, Demeler U, eds. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation und Refractive Chirurgie. Köln, Germany: Biermann Verlag; 2004;525-529.
37. Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003;29:1780-1785.
38. Spoerl E, Wollensak G, Dittert D-D, Seiler T. Thermomechanical behaviour of collagen-cross-linked porcine cornea. Ophthalmologica. 2004;218:136-140.
39. Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res. 2004;29:35-40.
40. Wollensak G, Wilsch M, Spoerl E, Seiler T. Collagen fiber diameter in the rabbit cornea after collagen crosslinking by riboflavin/UVA. Cornea. 2004;23:503-507.
41. Isenberg HD. ASM Clinical Microbiology Procedures Handbook. Vol. 1 2004:5.1.1-5.1.12.
42. National Committee for Clinical Laboratory Standards. Approved standard M2-A8. Performance Standards for Antimicrobial Disc Susceptibility Testing. 8th ed. Villanova, PA: NCCLS; 2003
43. National Committee for Clinical Laboratory Standards. Approved standard M7-A6. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 6th ed. Villanova, PA: NCCLS; 2003.
44. Herretes S, Suwan-Apichon O, Pirouzmanesh A, et al. Use of topical human amniotic fluid in the treatment of acute ocular alkali injuries in mice. Am J Ophthalmol. 2006;142:271-278.
45. O'Brien TP. Bacterial keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. Philadelphia: Mosby; 1997:1139-1189.
46. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979;24:105-116.
47. Ormerod D, Hertzmark E, Gomez DS, et al. Epidemiology of microbial keratitis in Southern California. Ophthalmology. 1987;94:1321-1333.
48. Gelender H, Rettich C. Gentamicin-resistant Pseudomonas aeruginosa corneal ulcers. Cornea. 1984;3:21-26.
49. Cameron JA, Antonios SR, Cotter JB, et al. Endophthalmitis from contaminated donor corneas following penetrating keratoplasty. Arch Ophthalmol. 1991;105:54-59.
50. Pitts DG, Cullen AP, Hacker PD. Ocular effects of ultraviolet radiation from 295-365 nm. Invest Ophthalmol Vis Sci. 1977;16:932-939.
51. Wollensak G, Spoerl E, Wilsch M, Seiler T. Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea. 2004;23:43-49.
52. Kumar V, Lockerbie O, Kell SD, et al. Riboflavin and UV light based pathogen reduction: extend and consequence of DNA damage at molecular level. Photochem Photobiol. 2004;75:561-564.
53. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:1496-1504.
54. Olsen EG, Ringvold A. Human cornea endothelium and ultraviolet radiation. Acta Ophthalmol (Copenh). 1982;60:54-56.
55. Daxecker F, Ambach W, Blumthaler M, et al. Spektrale ultraviolett- transmission des menschlichen auges. Spekt Augenheilkd. 1995;9:80-84.
56. Soderberg PG, Michael R, Merriam JC. Maximum acceptable dose of ultraviolet radiation: a safety limit for cataract. Acta Ophthalmol Scand. 2003;81:165-169.
57. Sliney DH. Ocular radiation hazards. In: Bass M, ed. Handbook of Optics. New York: Optical Society of America and McGraw-Hill; 2000:15.1-15.16.
58. Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007;26(4):385-389.
59. Bessey OA, Lowry, OH. Factors influencing the riboflavin content of the cornea. J Biol Chem. 1944;155:635-646.